The Vulvovaginal Candidiasis drugs in development market research report provides comprehensive information on the therapeutics under development for Vulvovaginal Candidiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Vulvovaginal Candidiasis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Vulvovaginal Candidiasis and features dormant and discontinued products.
GlobalData tracks 13 drugs in development for Vulvovaginal Candidiasis by 14 companies/universities/institutes. The top development phase for Vulvovaginal Candidiasis is phase ii with five drugs in that stage. The Vulvovaginal Candidiasis pipeline has 13 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Vulvovaginal Candidiasis pipeline products market are: Grupo Ferrer Internacional, Mycovia Pharmaceuticals and Osel.
The key targets in the Vulvovaginal Candidiasis pipeline products market include Lanosterol 14 Alpha Demethylase (Sterol 14 Alpha Demethylase or Cytochrome P450 14DM or Cytochrome P450LI or Cytochrome P450 51A1 or CYPLI or CYP51A1 or EC 1.14.14.154), Ergosterol , and Prostaglandin G/H Synthase 2 (Cyclooxygenase 2 or COX2 or Prostaglandin Endoperoxide Synthase 2 or PHS II or Prostaglandin H2 Synthase 2 or PTGS2 or EC 1.14.99.1).
The key mechanisms of action in the Vulvovaginal Candidiasis pipeline product include Lanosterol 14 Alpha Demethylase (Sterol 14 Alpha Demethylase or Cytochrome P450 14DM or Cytochrome P450LI or Cytochrome P450 51A1 or CYPLI or CYP51A1 or EC 1.14.14.154) Inhibitor with four drugs in Phase III. The Vulvovaginal Candidiasis pipeline products include four routes of administration with the top ROA being Vaginal and three key molecule types in the Vulvovaginal Candidiasis pipeline products market including Small Molecule, and Synthetic Peptide.
Vulvovaginal Candidiasis overview
An excessive growth of yeast in the vagina that results in irritation, a local fungal infection caused by the Candida genus. It is most commonly seen in females in high estrogen states, pregnancy, oral contraceptive use, obesity, diabetes mellitus. It is not considered an STI although it can be transmitted by sexual intercourse.
For a complete picture of Vulvovaginal Candidiasis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
